NCT01495598View on ClinicalTrials.gov

Pomalidomide for Kaposi Sarcoma in People With or Without HIV

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

January 10, 2012

Primary Completion Date

May 17, 2022

Study Completion Date

May 17, 2022

Conditions
Kaposi SarcomaSarcoma, Kaposi
Interventions
DRUG

Pomalidomide

5 mg by mouth (p.o.) for 21 of 28 days

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT01495598 - Pomalidomide for Kaposi Sarcoma in People With or Without HIV | Biotech Hunter | Biotech Hunter